Skip to main navigation
  • Follow Us:
  • Grant Portal
Catalystpharma.com

Corporate Menu

  • About Catalyst
    • History
    • Management
    • Board Of Directors
    • News & Events
    • Careers
    • Contact Us
  • Patient Focus
    • Patient Stories
      • LEMS Stories
    • Disease Information
      • LEMS
      • MuSK-MG
      • SMA
    • Patient Resources
      • Organizations
      • Event Calendar
      • Patient Engagement
  • Research & Pipeline
    • Roadmap To Success (Strategy)
    • Pipeline (clinical)
      • LEMS Clinical
      • MuSK-MG Clinical
      • SMA Clinical
    • Product
    • Business Development
    • Healthcare Professional Outreach
  • Clinical Trials
  • Responsibility
    • Corporate Giving
    • Investigator Sponsored Research
  • Investors
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Stock Information
      • Historic Stock Lookup
    • Annual Report and Proxy
    • Analyst Coverage
    • Email Alerts
Select Page
EPS Fully Diluted (TTM)

Mobile Menu

  • Press Releases
  • Events & Presentations
  • SEC Filings
  • Corporate Governance
  • Stock Information
  • Annual Report and Proxy
  • Analyst Coverage
  • Email Alerts

EPS Fully Diluted (TTM)

This is the Adjusted Income Available to Common Stockholders for the trailing twelve months divided by the trailing twelve month Diluted Weighted Average Shares Outstanding.

Toolkit

  • Email Alerts

  • RSS

  • Print page

  • Search

Footer Menu

  • ABOUT CATALYST
  • PATIENT FOCUS
  • RESPONSIBILITY
  • RESEARCH & PIPELINE
  • NEWS & EVENTS
  • CAREERS
  • CONTACT US
  • CLINICAL TRIALS
CONTACT
(305) 420-3200
Email Us


FOLLOW US:
facebook twitter linkedin
© 2020 Catalyst Pharmaceuticals, Inc. All Rights Reserved. 19CRP0211(3) November 2019 | Privacy Policy | Accessibility Statement